Berkeley Lights to Participate in the Morgan Stanley 2020 Healthcare Conference
Berkeley Lights, a leader in Digital Cell Biology, will participate in the Morgan Stanley Virtual Healthcare Conference on September 15, 2020, at 8:00 a.m. Pacific Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Berkeley Lights, a leader in Digital Cell Biology, will participate in the Morgan Stanley Virtual Healthcare Conference on September 15, 2020, at 8:00 a.m. Pacific Time. The management team will engage in a fireside chat, which can be accessed via a live and archived webcast on their website. Berkeley Lights focuses on accelerating biotherapeutics development through its innovative platform, which captures critical data from single cells. Their technology aims to set industry standards in cell-based product development.
Details
News Market Reaction – BLI
The recorded move for BLI in the trading session of this news was +1.99%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.
Berkeley Lights’ management is scheduled for a fireside chat on Tuesday, September 15 at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.berkeleylights.com.
About Berkeley Lights
Berkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information for thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. Our platform is a fully integrated, end-to-end solution, comprising proprietary consumables, including our OptoSelect chips and reagent kits, advanced automation systems, and application software. We developed the Berkeley Lights Platform to provide the most advanced environment for rapid functional characterization of single cells at scale, the goal of which is to establish an industry standard for our customers throughout their cell-based product value chain.
Berkeley Lights’ Beacon and Lightning systems and Culture Station instrument are: FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
Press Contact
berkeleylights@bulleitgroup.com
Investor Contact
ir@berkeleylights.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.